Zhu-Lin Liu1, Ting-Ting Zeng2, Xiao-Juan Zhou1, Ya-Nv Ren2, Lei Zhang2, Xin-Xing Zhang1, Zhen-Yu Ding1. 1. Division of Thoracic Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu - China. 2. Department of Laboratory Medicine, State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu - China.
Abstract
BACKGROUND: Lung cancer ranks first both in morbidity and mortality in malignancies, but prognostic biological markers are lacking. The neutrophil-lymphocyte ratio (NLR) was proposed as a convenient biological marker. This study aimed to explore the prognostic value of NLR in advanced non-small cell lung cancer (NSCLC). METHODS: This retrospective study screened patients admitted from October 2007 to October 2014. Patients had histopathologically confirmed, treatment-naïve, metastatic NSCLC, and were prescribed platinum doublet chemotherapy. NLR and demographic data were collected, together with the outcome of chemotherapy. Progression-free survival (PFS) and overall survival (OS) were analyzed using the Kaplan-Meier method and Cox regression model. RESULTS: A total of 325 patients were enrolled. The cutoff value for NLR (3.19) was determined by receiver operator characteristic analysis. Patients were dichotomized into high (≥3.19) and low (<3.19) NLR groups. Both groups had similar demographic features. However, the low-NLR group had longer PFS (6.1 months) and OS (22.3 months) than the high-NLR group (5.1 months, p = 0.002; 13.1 months, p<0.001, respectively). Multivariate analysis confirmed that NLR was inversely related to the prognosis of these patients (HR = 1.684, 95%: 1.297-2.185, p<0.001). CONCLUSIONS: This study argues that NLR is a convenient prognostic biological marker for advanced NSCLC patients treated with first-line chemotherapy and warrants further validation.
BACKGROUND:Lung cancer ranks first both in morbidity and mortality in malignancies, but prognostic biological markers are lacking. The neutrophil-lymphocyte ratio (NLR) was proposed as a convenient biological marker. This study aimed to explore the prognostic value of NLR in advanced non-small cell lung cancer (NSCLC). METHODS: This retrospective study screened patients admitted from October 2007 to October 2014. Patients had histopathologically confirmed, treatment-naïve, metastatic NSCLC, and were prescribed platinum doublet chemotherapy. NLR and demographic data were collected, together with the outcome of chemotherapy. Progression-free survival (PFS) and overall survival (OS) were analyzed using the Kaplan-Meier method and Cox regression model. RESULTS: A total of 325 patients were enrolled. The cutoff value for NLR (3.19) was determined by receiver operator characteristic analysis. Patients were dichotomized into high (≥3.19) and low (&lt;3.19) NLR groups. Both groups had similar demographic features. However, the low-NLR group had longer PFS (6.1 months) and OS (22.3 months) than the high-NLR group (5.1 months, p = 0.002; 13.1 months, p&lt;0.001, respectively). Multivariate analysis confirmed that NLR was inversely related to the prognosis of these patients (HR = 1.684, 95%: 1.297-2.185, p&lt;0.001). CONCLUSIONS: This study argues that NLR is a convenient prognostic biological marker for advanced NSCLCpatients treated with first-line chemotherapy and warrants further validation.
Authors: Hossein Maymani; Kenneth Hess; Roman Groisberg; David S Hong; Aung Naing; Sarina Piha-Paul; Filip Janku; Siqing Fu; Apostolia M Tsimberidou; Shubham Pant; Daniel Karp; Shuang Liu; Ming Sun; John Heymach; George Simon; Funda Meric-Bernstam; Vivek Subbiah Journal: Lung Cancer Date: 2018-04-11 Impact factor: 5.705
Authors: Hanno M Witte; Bastian Bonorden; Armin Riecke; Harald Biersack; Konrad Steinestel; Hartmut Merz; Alfred C Feller; Veronica Bernard; Sebastian Fetscher; Nikolas von Bubnoff; Niklas Gebauer Journal: Cancers (Basel) Date: 2020-04-09 Impact factor: 6.639